On a commercial premix line, chlortetracycline hydrochloride veterinary API is charged into a 500-kg ribbon blender after the carrier, usually ground calcium carbonate or rice husk, has been pre-screened through a 0.8-mm conical sieve. Batch potency is standardized to 10–110 g/kg chlortetracycline activity by correcting the API charge for assay, moisture, and residual solvent. Mixing is run for 12–20 min at 20–25 rpm. Blend uniformity samples are taken from 10 cross-sectional points, and the batch is rejected if relative standard deviation exceeds 5.0%. Mineral oil at 1.0–2.0 wt% may be added after the 6-minute mark as a dust suppressant, but staged addition is used to prevent hydrophobic film formation on CTC particles, which would delay release in the proximal gastrointestinal tract.

Feed pelleting introduces the main process conflict. Steam conditioning at 70–85°C raises moisture to 15–17% and accelerates epimerization of chlortetracycline to 4-epichlortetracycline. A dwell time above 20–30 s in the conditioner or a pellet press die retention above 10–15 s can produce assay loss above 5%, visible as a shift from yellow to brown and a reduction in microbiological activity. Production lines that cannot bypass pelleting cap die temperature below 60°C and hold cooler discharge moisture at 10–12%. Registered medicated feed use is bound by 21 CFR 558.128, with manufacturing controls under 21 CFR Part 225 and EU authorization under Regulation (EC) No 1831/2003. Sampling is performed according to ISO 6497.

What Limits Stock Solution Stability in CTC Drinking-Water Premixes?

Water medication with chlortetracycline hydrochloride demands a concentrated stock solution because final drinker concentrations are generally 50–400 mg/L for swine and poultry, depending on body weight and water intake. The hydrochloride salt gives a stock pH of approximately 2.3–3.0 at 25 g/L. This acidic environment slows epimerization but attacks galvanized nipples and unprotected aluminium drinker lines when undiluted stock is flushed through the distribution loop. Field failures occur when the stock solution is prepared in hard water with carbonate alkalinity above 200 mg CaCO₃/L. Neutralization in the stock tank precipitates free base and calcium-chelated complexes, leaving an orange film on the bottom and lowering the dose delivered to the animals. In-line proportioners are therefore calibrated against the actual water source at the point of use, not against deionized water.

Photodegradation is controlled by holding the working solution in opaque polyethylene tanks and consuming the preparation within 24 h. Loss of assay potency is measured by stability-indicating HPLC with UV detection at 365 nm. Published data for all regional water matrices is limited, so a pilot spiking study is performed before line installation. The acceptance criterion is typically ≥ 95.0% label recovery at 4 h in the target water. Soluble powder packaging is tested for water activity below 0.60 and seal integrity, with finished goods stored below 30°C in moisture-tight laminate sachets. The bulk powder is blended in a low-shear tumble mixer, and liquid lactose or maltodextrin is omitted because reducing sugars accelerate browning in humid air.

If Terminal Sterilization Is Proposed for CTC Injection, pH and Headspace Oxygen Control Must Be Locked Before Fill

Injectable formulations of chlortetracycline hydrochloride are prepared by dissolving the API in Water for Injection at 5–100 mg/mL chlortetracycline activity, depending on the target species and route. The pH is adjusted with 0.1 N hydrochloric acid or 0.1 N sodium hydroxide to a narrow range of 2.5–3.5. Above pH 4.5, reversible epimerization and insoluble degradation products reduce the amount of microbiologically active CTC and create visible precipitation. Formulation development data indicate that moist-heat terminal sterilization is generally avoided. If terminal sterilization is proposed, a sealed vial study at 121°C for 15 min must demonstrate not more than 5.0% total related substances and no visible precipitation. Published data for terminal sterilization of this specific veterinary CTC hydrochloride injection configuration is limited, so aseptic filtration through 0.45 µm followed by 0.22 µm polyethersulfone capsules is the standard route used in registered lines.

Fill-and-finish occurs in amber Type I glass vials under nitrogen overlay. Residual headspace oxygen is kept at or below 2.0% by a 3-cycle vacuum-nitrogen purge. The closure is chlorobutyl with a fluoropolymer coating to limit oxygen ingress and metal extractables. Release tests include USP <1>, USP <71>, USP <85>, and USP <788>. A limulus amebocyte lysate acceptance limit is set from the market authorization file and the maximum dose. Diluent compatibility is restricted to 5% dextrose injection or 0.9% sodium chloride injection. Lactated Ringer’s solution is incompatible because calcium-containing diluents chelate the CTC and form poorly soluble aggregates that may obstruct intravenous catheters.

Roller-Compacted CTC Tablet Granulation: Shear, Moisture, and Dissolution Boundaries

Direct compression of chlortetracycline hydrochloride API is impractical at industrial scale because the unmilled powder has low bulk density and poor flow, producing weight variation above 5% when run on a rotary press above 30 rpm. Roller compaction is therefore used to produce a granule fraction between 200 µm and 800 µm, with ribbon density held at 1.10–1.20 g/cm³. Milled granules are blended with microcrystalline cellulose and crospovidone. Dicalcium phosphate is excluded from the formulation because calcium and phosphate moieties compete for CTC chelation and reduce dissolution recovery. The lubricant is sodium stearyl fumarate or magnesium stearate at 0.5–1.0 wt%, added in the final 3–5 min of blending to avoid hydrophobic coating of the active.

Tablet hardness is set at 60–100 N and friability below 1.0%. Release acceptance references USP <701>, USP <711>, and USP <905>. Dissolution is run in 900 mL of 0.1 N HCl at 37 ± 0.5°C using Apparatus 2 at 50 rpm. Over-compacted dense granules slow release below 80% at 45 min, and the roll force or screen is then reevaluated until the Q-value is met. Capsule filling with CTC powder requires relative humidity below 45% in the encapsulation suite because the hydrochloride salt adsorbs moisture rapidly and becomes sticky on contact with gelatin shells. A size 1 two-piece hard gelatin shell is commonly used for 100 mg strength, with fill weight adjusted by tapped bulk density rather than raw API weight.

Dry granulation becomes the default route when the formulation brief calls for an oral granule packed into 10-g aluminium or polylaminate stick packs. The API is first milled through a 0.5-mm screen, then dry-blended with sucrose or sorbitol, citric acid, and a non-reducing flavouring system. Binder is added as an aqueous povidone K30 solution at 5–8% solids. The wet mass is dried at inlet air temperature below 65°C until loss on drying reaches 1.0–2.0%. Product temperature is controlled below 45°C throughout because chlortetracycline discolours rapidly in warm, humid air. The resulting granules are sized through a 1.0-mm oscillating sieve and filled volumetrically. Content uniformity is determined according to USP <905> on 10 units, and fill weight is adjusted using granule density after each batch because API density varies with crystal habit.

Oral pastes for horses or calves are made by dispersing the milled CTC API into a non-aqueous vehicle of medium-chain triglycerides and colloidal silica at 5–8% w/w. The paste is filled into dial-a-dose polyethylene syringes. Rheology is checked with a Brookfield viscometer at 25°C using a T-bar spindle at 5 rpm. Yield stress is adjusted between 30 Pa and 70 Pa to ensure the dose remains on the tongue after extrusion but can be discharged through a 6-mm orifice at 10–20 N manual force. Aluminium-containing suspending agents are avoided because trivalent aluminium binds tetracyclines and lowers oral bioavailability. Stability samples are stored at 25°C/60% RH and 40°C/75% RH for 6 months, with moisture ingress reported as mass gain not exceeding 0.5% in the primary package.

Dry Suspension Ointment Compounding Requires Anhydrous Levigation and Controlled Particle Size

Because the free water in a conventional emulsion or gel would hydrolyze the molecule within days, topical veterinary ointment based on chlortetracycline hydrochloride API uses an anhydrous base. The API is jet-milled to a particle size distribution with D90 ≤ 15 µm, then levigated into white petrolatum or a 70:30 PEG 4000–PEG 400 base. Levigation is performed in a low-shear planetary mixer at 20–30 rpm, with the API pre-wet with a portion of liquid paraffin or PEG 400 to prevent dusting. Final ointment strength is usually 1–3% w/w chlortetracycline hydrochloride. The paste is milled once through a three-roller mill with a roller gap of 20–40 µm to eliminate agglomerates. Controlled temperature is necessary because the base softens above 40°C and the API is thermally labile.

Release testing follows USP <795> for nonsterile compounded preparations where the product is extemporaneously prepared, or the finished product monograph if registered. A USP monograph for this exact chlortetracycline ointment strength is not referenced, so in-house specifications are set for assay, spreadability, and anhydrous base melting range. Metal or plastic ointment tubes are filled by a piston filler. Stainless steel contact surfaces are passivated, and aluminium tubes are lined with an epoxy-phenolic lacquer because CTC hydrochloride in an acidic PEG base can corrode unlined aluminium. Storage is restricted to 25°C in tight, light-resistant containers, with a use period not exceeding 90 days after first opening unless preservative efficacy data support a longer interval.